Quarterly ResultMay 14, 2026, 04:23 PM
Eton Pharma Q1 Net Income $1.55M; Revenue $24.27M, up 40.4%
AI Summary
Eton Pharmaceuticals reported a net income of $1.55 million for Q1 2026, a significant improvement from a net loss of $1.57 million in Q1 2025. Total net revenues increased by 40.4% to $24.27 million, driven by strong product sales. The company also completed the acquisition of U.S. rights to HEMANGEOL® for $14 million during the quarter, contributing to a decrease in cash and cash equivalents despite strong operating cash flow.
Key Highlights
- Net income for Q1 2026 was $1.55 million, compared to a net loss of $1.57 million in Q1 2025.
- Total net revenues increased 40.4% to $24.27 million in Q1 2026 from $17.28 million in Q1 2025.
- Product sales and royalties, net, rose to $24.27 million in Q1 2026 from $14.00 million in Q1 2025.
- Gross profit increased 49.4% to $14.74 million in Q1 2026 from $9.86 million in Q1 2025.
- Basic net income per share was $0.06 for Q1 2026, up from a loss of $0.06 per share in Q1 2025.
- Acquired U.S. rights to HEMANGEOL® for $14.00 million and other product license rights for $1.00 million.
- Net cash from operating activities was $7.41 million, up from $2.09 million in Q1 2025.
- Cash and cash equivalents stood at $19.66 million as of March 31, 2026.
Price Impact
More from ETON